drugset

drugset / Trial / NCT03394196

RESIST-2: 2nd-line ART for HIV-2 Infection

NCT03394196 ↗

Terminated 152 enrolled University of Washington Centre de Sante de Ziguinchor, Casamance, Senegal · collab Clinique des Maladies Infectieuses, CHNU de Fann, Dakar, Senegal · collab Janssen Pharmaceutica · collab Merck Sharp & Dohme LLC · collab National Institute of Allergy and Infectious Diseases (NIAID) · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Prospective, longitudinal, open label, HIV-2 viral load and antiretroviral resistance informed 2nd-line ARV implementation study.

Timeline

Start: 2018-07-04
Primary completion: 2020-05-31
Completion: 2020-05-31

Publications

Raugi DN, Diallo K, Diallo MB, Faye D, Cisse O, Smith RA, Sall F, Sall EHI, Faye K, Diatta JP, Diaw B, Sambou J, Malomar JJ, Hawes SE, Seydi M, Gottlieb GS; University of Washington-Senegal HIV-2 Study Group. Resource and infrastructure challenges on the RESIST-2 Trial: an implementation study of drug resistance genotype-based algorithmic ART switches in HIV-2-infected adults in Senegal. Trials. 2021 Dec 18;22(1):931. doi: 10.1186/s13063-021-05902-5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Darunavir	Small molecule	600 mg	—
Subject	Lamivudine	Other / unclassified	150 mg	—
Subject	Lamivudine	Other / unclassified	300 mg	—
Subject	Lopinavir	Other / unclassified	400 mg	—
Subject	Raltegravir	Other / unclassified	400 mg	—
Subject	Ritonavir	Other / unclassified	100 mg	—
Subject	Tenofovir disoproxil fumarate	Small molecule	300 mg	—
Subject	Zidovudine	Small molecule	300 mg	—
Subject	emtricitabine	Other / unclassified	200 mg	—

Indications

No indication recorded.